Extended Data Table 1 Summary of responses by investigator assessments

From: First-line cadonilimab plus chemotherapy in HER2-negative advanced gastric or gastroesophageal junction adenocarcinoma: a randomized, double-blind, phase 3 trial

  1. PD-L1, programmed death ligand 1; CPS, combined positive score; CI, confidence interval.
Back to article page